| Pair Name | Bufalin, Gemcitabine | ||
| Phytochemical Name | Bufalin (PubChem CID: 9547215 ) | ||
| Anticancer drug Name | Gemcitabine (PubChem CID: 60750 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Bufalin, Gemcitabine | |||
| Disease Info | [ICD-11: 2C10.0] | Pancreatic ductal adenocarcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | MAP3K5 | hsa4217 |
| In Vitro Model | BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 |
| MIA PaCa-2 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0428 | |
| PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
| In Vivo Model | To establish xenograft model, each mouse was subcutaneously injected with 6×10⁶ Mia PaCa-2 cells in the back. | |||
| Result | These results suggest that bufalin may be a potential chemotherapeutic agent for pancreatic cancer, which could enhance the antitumor efficacy of gemcitabine when used in combination, possibly through the activation of ASK1/JNK. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancerBufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol Lett. 2012 Oct;4(4):792-798. doi: 10.3892/ol.2012.783. | Click |
